Insider Trading April 17, 2026 06:47 PM

Ensign Group Director Sells $19,660 in Stock Ahead of Earnings; Recent Grant Also Recorded

Director Mark Vincent Parkinson trims holding by 100 shares while a separate 600-share award vests over three years; company posts mixed Q4 2025 results and faces an upcoming report

By Hana Yamamoto ENSG
Ensign Group Director Sells $19,660 in Stock Ahead of Earnings; Recent Grant Also Recorded
ENSG

Mark Vincent Parkinson, a director at The Ensign Group (ENSG), sold 100 shares on April 16, 2026 for $196.60 each, netting $19,660 and leaving him with 3,400 shares. Parkinson also received a 600-share grant on April 15, 2026 that vests in three equal annual installments beginning April 15, 2027. The stock trades around $200.11, up 57% over the past year, while third-party analysis flags the shares as overvalued with a reported P/E of 34.37. The company reported Q4 2025 adjusted EPS of $1.82, beating estimates by 4% despite a slight revenue shortfall, and has an earnings release scheduled for April 23.

Key Points

  • Ensign director Mark Vincent Parkinson sold 100 shares on April 16, 2026 at $196.60, totaling $19,660; he now owns 3,400 shares.
  • Parkinson received a 600-share grant on April 15, 2026 that vests in three equal annual installments starting April 15, 2027.
  • The Ensign Group reported Q4 2025 adjusted EPS of $1.82 versus $1.75 expected, with revenue of $1.36 billion missing the $1.37 billion estimate; Truist raised its price target from $200 to $215 but kept a Hold rating.

Mark Vincent Parkinson, serving on the board of The Ensign Group (NASDAQ: ENSG), completed a sale of 100 shares of the company's common stock on April 16, 2026. The transaction was executed at $196.60 per share, producing gross proceeds of $19,660. Following the disposition, Parkinson's direct ownership in Ensign stands at 3,400 shares.

One day earlier, on April 15, 2026, Parkinson was granted 600 shares of Ensign common stock. The award is subject to a vesting schedule that will release the shares in three equal annual installments beginning on April 15, 2027.


The move comes as Ensign's public shares are trading near $200.11, a price that reflects a 57% total return over the preceding 12 months. Independent analysis cited alongside market data indicates the stock appears overvalued relative to a stated Fair Value benchmark, and the shares are trading at a price-to-earnings ratio of 34.37.

Investors and observers will be watching the company closely: Ensign is set to report results on April 23. The timing of Parkinson's sale and the outstanding grant precede that scheduled release.


Recent company financials show mixed signals. For the fourth quarter of 2025, The Ensign Group reported adjusted earnings per share of $1.82, outperforming analyst expectations of $1.75 by approximately 4%. At the same time, revenue for the quarter came in at $1.36 billion, slightly below the $1.37 billion consensus estimate, representing a modest top-line miss.

The combination of an EPS beat and a revenue shortfall produced a favorable response in aftermarket trading. In the wake of these results, Truist Securities adjusted its price target for Ensign from $200 to $215 while retaining a Hold rating. Truist attributed the price-target revision to the company's stronger-than-expected bottom-line performance and improved margins.


No additional context about motivations for the director's sale or the grant recipients is provided in the filings. The company’s forthcoming earnings release on April 23 will offer the next official update to investors.

Risks

  • Upcoming earnings release on April 23 could introduce volatility around the stock as investors digest new company guidance and results.
  • Valuation concerns remain: external analysis identifies the shares as overvalued relative to Fair Value and notes a P/E ratio of 34.37, which may pressure investor sentiment in the finance and healthcare sectors.
  • The recent revenue shortfall against expectations highlights top-line sensitivity that could affect market reactions and analyst assessments in the healthcare and senior-care service markets.

More from Insider Trading

Aehr Test Systems Director Sells $2.125M in Stock as Company Logs Record Order and Mixed Quarterly Results Apr 17, 2026 Clene Inc. 10% Holder Ugwumba Chidozie Sells $251,897 in Stock Over Three Days Apr 17, 2026 Aehr Test Systems Director Disposes $139,922 in Shares; Company Posts Record Order and Strong Bookings Apr 17, 2026 StandardAero HR Chief Sells $20.9K in Shares as Company Posts Strong Q4 2025 Results Apr 17, 2026 Apogee CFO Disposes $180,000 in Stock as Shares Trade Near Yearly High Apr 17, 2026